Core Insights - The launch of Ryanodex® represents a significant advancement in emergency care for malignant hyperthermia in India, aiming to provide hope and critical treatment options [1][3] - The initiative is supported by key stakeholders, including the Indian Society of Anesthesiologists, which has been instrumental in building a national preparedness platform for managing malignant hyperthermia emergencies [2][4] Company Overview - Perin Healthcare is focused on delivering critical medicines and medical solutions across India, partnering with global innovators to enhance emergency preparedness and patient outcomes [6] - Eagle Pharmaceuticals is a fully integrated pharmaceutical company dedicated to developing innovative medicines that improve patients' lives [7] - ACA Pharma specializes in fast-track regulatory pathways and market access, facilitating patient access to medications in a timely manner across Greater China and Southeast Asia [8] Product Information - Ryanodex® (dantrolene sodium for injection) is FDA-approved for treating and preventing malignant hyperthermia, particularly in high-risk patients [9] Event Highlights - A nationwide professional launch event hosted by the Indian Society of Anesthesiologists took place on November 11, 2025, focusing on education regarding malignant hyperthermia recognition and response protocols [10]

Core Insights - ACA Pharma has entered into an exclusive distribution agreement with Eagle Pharmaceuticals to commercialize Ryanodex® and Barhemsys® in Hong Kong, Macau, Singapore, and Greater China [2][5][6] Product Overview - Ryanodex® (dantrolene sodium for injection) is indicated for the treatment and prevention of malignant hyperthermia, while Barhemsys® (amisulpride injection) is used for the prevention and treatment of postoperative nausea and vomiting (PONV) [3][9] - Both products have established use in the U.S. and are positioned for rapid market entry in Asia [3][5] Regulatory Progress - Ryanodex has completed fast-track registration in Macau, while Barhemsys is still undergoing registration processes in Macau, Hong Kong, and Singapore [4][5] - ACA Pharma is also pursuing national registration in China and aims to include both products on Hainan's Urgently Needed Clinical Medicines List for accelerated adoption [4][5] Market Positioning - Despite competition from local generics in China, imported originator medicines like Ryanodex and Barhemsys maintain a competitive edge in hospitals [5] - ACA Pharma plans to expand the distribution of both products into Latin America, Asia, Europe, and other regions through global alliances and fast-track pathways [5][6] Strategic Vision - The agreement allows ACA Pharma to provide healthcare professionals and patients with access to critical hospital medicines quickly, addressing urgent unmet needs across multiple regions [6] - ACA Pharma's established fast-track regulatory pathways enable patient access in as little as 30–90 days, targeting leading hospitals in the Greater Bay Area and beyond [7]